Open Scanner

Specify a stock or a cryptocurrency in the search bar to get a summary

Internet Computer ICP
Bitcoin Cash BCH
Litecoin LTC
Field stub for analysis

Alector Inc

ALEC
Current price
5.09 USD +0.03 USD (+0.59%)
Last closed 5.09 USD
Sector Healthcare
Industry Biotechnology
Exchange NASDAQ
Capitalization 576 410 752 USD
Yield for 12 month -22.53 %
1Y
3Y
5Y
10Y
15Y
ALEC
21.11.2021 - 28.11.2021

Alector, Inc., a clinical stage biopharmaceutical company, develops therapies for the treatment of neurodegeneration diseases. Its products include AL001, an immune activity in the brain with genetic links to multiple neurodegenerative disorders, which is in Phase III clinical trial for the treatment of frontotemporal dementia, Alzheimer's, Parkinson's, and amyotrophic lateral sclerosis diseases; and AL101 that is in Phase I clinical trial for the treatment of neurodegenerative diseases, including Alzheimer's and Parkinson's diseases. The company also offers AL002, a product candidate that is in Phase II clinical trial for the treatment of Alzheimer's disease. Alector, Inc. has a collaboration agreement with Adimab, LLC for the research and development of antibodies; and a strategic collaboration agreement with GlaxoSmithKline plc for the development and commercialization of monoclonal antibodies, such as AL001 and AL101 to treat neurodegenerative diseases. The company was founded in 2013 and is headquartered in South San Francisco, California. Address: 131 Oyster Point Boulevard, South San Francisco, CA, United States, 94080

Check your investment idea

Find the best to beat the market
TSLA TSLA Tesla Motors
AAPL AAPL Apple
MSFT MSFT Microsoft

Analytics

WallStreet Target Price

14.5 USD

P/E ratio

Dividend Yield

Current Year

+97 062 000 USD

Last Year

+133 617 000 USD

Current Quarter

+15 190 000 USD

Last Quarter

+9 109 000 USD

Current Year

+88 214 000 USD

Last Year

+133 617 000 USD

Current Quarter

+8 600 000 USD

Last Quarter

+6 852 000 USD

Key Figures ALEC

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
EBITDA -146 015 008 USD
Operating Margin TTM -312.4 %
PE Ratio
Return On Assets TTM -13.46 %
PEG Ratio
Return On Equity TTM -74.81 %
Wall Street Target Price 14.5 USD
Revenue TTM 97 062 000 USD
Book Value 1.58 USD
Revenue Per Share TTM 1.16 USD
Dividend Share
Quarterly Revenue Growth YOY 5.2 %
Dividend Yield
Gross Profit TTM -76 801 000 USD
Earnings Share -1.56 USD
Diluted Eps TTM -1.56 USD
Most Recent Quarter IV 2023
Quarterly Earnings Growth YOY -86.3 %
Profit Margin -134.34 %

Dividend Analytics ALEC

Dividend growth over 5 years

Continuous growth

Payout Ratio 5 years average

Dividend History ALEC

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Forward Annual Dividend Rate
Ex Dividend Date
Forward Annual Dividend Yield
Last Split Factor
Payout Ratio
Last Split Date
Dividend Date

Stock Valuation ALEC

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE
Forward PE 526.3158
Enterprise Value Revenue 0.6848
Price Sales TTM 5.9386
Enterprise Value EBITDA -0.4652
Price Book MRQ 4.2965

Financials ALEC

1 year
3 years
5 years
10 years
15 years
Results 2019 Dynamics
* The data for this period has not yet been published

Technical indicators ALEC

For 52 weeks

3.66 USD 9.07 USD
50 Day MA 6.27 USD
Shares Short Prior Month 5 846 246
200 Day MA 6.29 USD
Short Ratio 9.31
Shares Short 6 468 719
Short Percent 8.61 %

Dynamics of changes in the value of assets

Stocks


MSFT

MSFT

399.12 USD Microsoft Corporation -4.91 (-1.22%)
Detailed analytics

ETF funds


M

MDAXEX

207.85 CHF iShares MDAX UCITS ETF (DE) 0 (0%)
Detailed analytics

Metals


Gold

2175.88 USD Gold +5.94 (+0.27%)
Detailed analytics